Τίτλος:
Adriamycin in combination with dexamethasone and octreotide lacks activity on the treatment of a 4T1 metastatic breast cancer model
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The aim of this study was to evaluate whether the palliative treatment for metastatic disease with dexamethasone (DEX) plus octreotide (OCT) can improve the anticancer effects of the standard treatment with adriamycin (ADR) on a 4T1 metastatic breast cancer (MBC) model. 4T1 cells were first characterized for the expression of the somatostatin receptors 1-5 and were then inoculated onto the femur of BALB/C mice. Investigation protocols used 4T1 cell proliferation and invasion assays, analysis of radiographic images of the bone metastatic lesions, and overall survival of the diseased animals. The triple combination treatment regime (ADR+OCT+DEX) was ineffective for growth inhibition and showed an antagonistic effect on ADR activity in the 4T1 cell line in both proliferation and invasion assays. ADR treatment following the administration of the DEX+OCT regimen decreased the anticancer activity of ADR both on the grading of the bone metastatic lesions and on the overall survival of diseased animals. Moreover, the palliation treatment with OCT+DEX and in combination with ADR rather caused disease progression of the metastatic disease and bone lesions in a 4T1 MBC model in vivo. These results suggest that the administration of the DEX+OCT regimen, although may preserve palliative effects, neutralizes or reverses the anticancer effects of ADR on a 4T1 MBC model in vitro and in vivo. The simultaneous use of these drugs should be considered carefully in clinical practice. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
Συγγραφείς:
Dalezis, P.
Trafalis, D.T.
Geromichalos, G.D.
Pissimissis, N.
Panagiotopoulou, D.
Galaktidou, G.
Papageorgiou, E.
Papageorgiou, A.
Lymperi, M.
Koutsilieris, M.
Περιοδικό:
Anti-Cancer Drug Design
Εκδότης:
Lippincott Williams and Wilkins
Λέξεις-κλειδιά:
dexamethasone; doxorubicin; interleukin 6; octreotide; osteoclast differentiation factor; osteoprotegerin; somatomedin C; somatostatin receptor 1; somatostatin receptor 2; somatostatin receptor 3; somatostatin receptor 4; somatostatin receptor 5; antineoplastic agent; dexamethasone; doxorubicin; octreotide; somatostatin receptor; tumor marker, animal experiment; animal model; antineoplastic activity; Article; bone lesion; bone metastasis; bone radiography; cancer combination chemotherapy; cancer inhibition; cancer model; cancer palliative therapy; cancer survival; cell proliferation; controlled study; disease course; drug efficacy; female; human; human cell; IC50; in vitro study; in vivo study; metastatic breast cancer; mouse; nonhuman; overall survival; priority journal; tumor invasion; animal; Bagg albino mouse; blood; bone tumor; drug effects; drug interaction; experimental mammary neoplasm; metabolism; pathology; randomization; secondary; tumor cell line, Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Dexamethasone; Doxorubicin; Drug Interactions; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Octreotide; Random Allocation; Receptors, Somatostatin
DOI:
10.1097/CAD.0000000000000484
